GGrantIndex
Sort

8,912 grants matching sars cov 2

RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization

$5,848,902
Lucila Ohno-Machado · University Of California, San Diego · U24 · FY2022 · LM

Targeting druggable coronavirus proteins

$5,786,835
Michael R. Farzan · Scripps Research Institute, The · U19 · FY2022 · AI

UCSF COVID-19 Immunophenotyping Clinical Study and Core Laboratories

$5,742,559
David J Erle · University Of California, San Francisco · U19 · FY2020 · AI

Discovery of new antiviral methylase, protease, and helicase inhibitors of corona-, flavi-, and alphaviruses

$5,701,101
Thomas Tuschl · Hackensack University Medical Center · U19 · FY2022 · AI

RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization

$5,687,219
Lucila Ohno-Machado · Yale University · U24 · FY2023 · LM

RAPID ACCELERATION OF DIAGNOTICS (RADX) ADVANCED TECHNOLOGIES PLATFORM RAPID ACCELERATION OF DIAGNOTICS (RADX) ADVANCED TECHNOLOGIES PLATFORM PROJECT

$5,665,290
James Lu · Helix · N01 · FY2021 · HL

REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD

$5,665,215
E Wesley Ely · Vanderbilt University Medical Center · R01 · FY2024 · AG

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC

$5,663,427
Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI

Structural biology core

$5,661,828
David A Agard · University Of California, San Francisco · U19 · FY2022 · AI

Core C: Vaccine production and process development

$5,637,003
Lauren Carter · University Of Washington · U19 · FY2024 · AI

Experimental and Computational Analysis of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) Cohort

$5,634,911
Donald Ym Leung · National Jewish Health · UM1 · FY2021 · AI

Pandemic Assistance Core

$5,598,964
Catherine A Blish · Stanford University · U19 · FY2022 · AI

Clinical and biomarker studies in Alzheimer's disease and related disorders

$5,587,710
Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2023 · AG

Animal Model Core

$5,580,377
David S Perlin · Hackensack University Medical Center · U19 · FY2022 · AI

Neuropathogenesis of Retroviral Infections

$5,580,007
Avindra Nath · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS

Serological Science for COVID-19 SeroNet

$5,554,144
Leonard Freedman · Leidos Biomedical Research, Inc. · N01 · FY2020 · CA

RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY

$5,505,000
Todd Woodrich · · N02 · FY2021 · HL

RADx-UP SAY YES COVID Test Study (S4)

$5,500,000
Michael Cohen-Wolkowiez · Duke University · U24 · FY2021 · MD

Targeting Viral RNA Using a Sequence Programmable Small Molecule-Oligonucleotide Conjugate

$5,450,416
Kevan M. Shokat · University Of California, San Francisco · U19 · FY2022 · AI

Implementation and Real-World Effectiveness of Monoclonal Antibodies to Treat High-Risk Outpatients with COVID-19

$5,449,454
Ronald J Sokol · University Of Colorado Denver · UL1 · FY2021 · TR

Pharmacokinetics and Drug Metabolism

$5,444,464
Xin Xu · National Center For Advancing Translational Sciences · ZIA · FY2023 · TR

Population-based survey of SARS-CoV-2 infection and immune response

$5,429,240
Aaron Julius Siegler · Emory University · R01 · FY2020 · AI

Project 3 – Direct-Acting Antivirals against Paramyxoviruses

$5,393,007
Benhur Lee · Emory University · U19 · FY2022 · AI

Convalescent Plasma to Limit Coronavirus Associated Complications: Randomized Blinded Phase 2 Study Comparing Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 Hospitalized Patients

$5,391,810
Ralph Lewis Sacco · University Of Miami School Of Medicine · UL1 · FY2020 · TR

Scanning Probe Microscopy for the Intramural Research Community

$5,358,669
Emilios K Dimitriadis · National Institute Of Biomedical Imaging And Bioengineering · ZIC · FY2023 · EB